CMVLF Recent News Cellectis and Servier announce
Post# of 4
Posted On: 03/04/2014 4:54:30 PM
CMVLF Recent News
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors Business Wire - Mon Feb 17, 1:03PM CST
US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases Business Wire - Wed Feb 05, 11:00AM CST
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models Business Wire - Tue Feb 04, 11:44AM CST
Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing Business Wire - Thu Jan 30, 12:00AM CST
Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays Business Wire - Fri Jan 17, 11:00AM CST
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program Business Wire - Thu Jan 09, 10:59AM CST
Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Depots, by Contributing Ectycell's Shares to Cellectis Bioresearch Business Wire - Tue Jan 07, 11:00AM CST
Competitor Analysis: CD19-Targeted Therapeutics M2 - Fri Nov 08, 4:27AM CST
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia Business Wire - Thu Jul 04, 11:00AM CDT
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production Business Wire - Wed Jun 26, 1:22PM CDT
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors Business Wire - Mon Feb 17, 1:03PM CST
US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases Business Wire - Wed Feb 05, 11:00AM CST
Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models Business Wire - Tue Feb 04, 11:44AM CST
Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing Business Wire - Thu Jan 30, 12:00AM CST
Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays Business Wire - Fri Jan 17, 11:00AM CST
Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program Business Wire - Thu Jan 09, 10:59AM CST
Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Depots, by Contributing Ectycell's Shares to Cellectis Bioresearch Business Wire - Tue Jan 07, 11:00AM CST
Competitor Analysis: CD19-Targeted Therapeutics M2 - Fri Nov 08, 4:27AM CST
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia Business Wire - Thu Jul 04, 11:00AM CDT
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production Business Wire - Wed Jun 26, 1:22PM CDT
(0)
(0)Cellectis Romainville (CMVLF) Stock Research Links
Scroll down for more posts ▼